Abstract
Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins.
We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved.
Keywords: Cardiovascular diseases, hyperlipidemia, low-density lipoprotein, low-density lipoprotein receptor, proprotein convertase subtilisin/ kexin 9, statins.
Current Pharmaceutical Design
Title:PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Volume: 19 Issue: 21
Author(s): Maciej Banach, Manfredi Rizzo, Milan Obradovic, Giuseppe Montalto, Jacek Rysz, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Cardiovascular diseases, hyperlipidemia, low-density lipoprotein, low-density lipoprotein receptor, proprotein convertase subtilisin/ kexin 9, statins.
Abstract: Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins.
We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved.
Export Options
About this article
Cite this article as:
Banach Maciej, Rizzo Manfredi, Obradovic Milan, Montalto Giuseppe, Rysz Jacek, P. Mikhailidis Dimitri and R. Isenovic Esma, PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/10.2174/13816128113199990303
DOI https://dx.doi.org/10.2174/13816128113199990303 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Novel approaches to examine the regulation of voltage-gated calcium channels in the heart
Current Molecular Pharmacology A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Cardiac Remodeling Induced by Smoking: Concepts, Relevance, and Potential Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design Transition of Care for Patients with Diabetes
Current Diabetes Reviews Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Microcirculation Dysfunction: A Possible Mechanism Responsible for Reverse Redistribution in Myocardial Perfusion Imaging?
Current Medical Imaging Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Pearls from the First Gulf Cardiac Amyloidosis Summit 2021
New Emirates Medical Journal Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews